James Jan Takasugi

This inventor holds 24 USPTO granted patents and 4 published patent applications, plus 2 CIPO patents and 2 EPO patents, primarily in Pharmaceutical Compositions. Top assignees: Ptc Therapeutics, Inc., Basf Aktiengesellschaft, Amgen Inc.. Active years: 2003-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: James Jan Takasugi. Retrieved from https://idiyas.com/inventor/james-jan-takasugi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 24 (Patent Applications = 4)

% Patents Active = 54.2

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 2

Average Co-Inventor Count = 5.3

ph-index = 6

Forward Citations = 107(Granted Patents)

Location History:

Trenton, NJ (US) (2011)
Lawrenceville, NJ (US) (2003 - 2020)

Company Filing History:

21 out of 186

Ptc Therapeutics, Inc.

patents

3 out of 10,816

Basf Aktiengesellschaft

where one patent can have more than one assignee

Years Active: 2003-2020

Loading Chart...

Areas of Expertise:

Pharmaceutical Compositions

Nonsense Suppression

Antiviral Treatment

1,2,4-Oxadiazole

Benzoic Acid

Ureido Compounds

Hepatitis C

Nucleoside Compounds

Somatic Mutations

Indole Derivatives

Acetylamino Benzoic Acid

Uracil Substituted Compounds

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10618877 - Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid (2020-04-14),

2. 10233161 - Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid (2019-03-19),

3. 9873677 - Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid (2018-01-23),

4. 9289398 - Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith (2016-03-22),

5. 9273076 - Compounds for nonsense suppression, and methods for their use (2016-03-01),

6. 8735414 - Indole derivatives and methods for antiviral treatment (2014-05-27),

7. 8710031 - Compounds for nonsense suppression and methods for their use (2014-04-29),

8. 8367841 - Processes for the preparation of 1,2,4-oxadiazole benzoic acids (2013-02-05),

9. 8334313 - Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease (2012-12-18),

10. 8013006 - Methods for treating hepatitis C (2011-09-06),

11. 7973069 - Methods for treating hepatitis C (2011-07-05),

12. 7902241 - Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease (2011-03-08),

13. 7902235 - Compounds for nonsense suppression, and methods for their use (2011-03-08),

14. 7868037 - Methods for treating hepatitis C (2011-01-11),

15. 7781478 - Methods for treating hepatitis C (2010-08-24),

Title: James Jan Takasugi: Innovator in Pharmaceutical Advancements

Introduction

James Jan Takasugi, based in Trenton, NJ, is a prolific inventor known for his significant contributions to the field of pharmaceuticals. With an impressive portfolio of 24 patents, Takasugi has demonstrated a commitment to innovation and medical advancement.

Latest Patents

One of Takasugi's recent inventions focuses on pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid. These compositions comprise the compound or its pharmaceutically acceptable salts, aimed at treating or preventing diseases associated with nonsense mutations or premature stop codons. The patent outlines methods for creating these compositions and administering them to patients, showcasing Takasugi's dedication to addressing genetic diseases through innovative pharmaceutical solutions.

Career Highlights

Throughout his career, Takasugi has worked with prominent companies in the pharmaceutical sector, including PTC Therapeutics, Inc. and BASF Aktiengesellschaft. His work at these organizations has allowed him to collaborate on groundbreaking projects and develop novel therapeutic solutions.

Collaborations

In his journey as an inventor, Takasugi has collaborated with esteemed colleagues, including Ellen Welch and Richard Gerald Wilde. These partnerships highlight the importance of teamwork in driving innovations that lead to improved healthcare outcomes.

Conclusion

James Jan Takasugi stands out as an influential figure in the pharmaceutical industry, with a robust patent portfolio that reflects his innovative spirit and commitment to addressing complex medical challenges. His work continues to inspire future advancements in the field.

Profile summary based on public USPTO records.